Highlights Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Market Closed - Euronext Paris Other stock markets 10:35:50 2024-04-29 am EDT			5-day change	1st Jan Change
0.388 ^EUR	-0.51%		-0.51%	-17.62%

Apr. 29	Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	CI
Apr. 25	Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mauna Kea Technologies SA Announces the Opening of A French Center of Excellence for the Use of Cellvizio in Lung Cancer Diagnostics	Apr. 29	CI
Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024	Apr. 25	CI
Mauna Kea: first Italian center for Cellvizio	Apr. 03	CF
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio	Mar. 27	CI
Mauna Kea: partnership with Metrodora Institute in the USA	Mar. 06	CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults	Mar. 06	CI
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals	Nov. 13	MT
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery	Nov. 13	CI
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer	Nov. 02	CI
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone	23-09-19	CI
Mauna Kea Technologies to Transfer Shares to Euronext Growth Paris	23-08-04	MT
Mauna Kea Technologies Announces the Installation of Cellvizio at University College Cork - APC Microbiome Ireland for Inflammatory Bowel Disease Applications	23-07-03	CI
Mauna Kea Technologies Shareholders Approve Transfer of Listing to Euronext Growth Paris	23-06-09	MT
Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®	23-06-01	CI
Mauna Kea Technologies Plans to Move Listing to Euronext Growth Paris	23-04-27	MT
Mauna Kea Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
Mauna Kea Technologies SA Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer	23-01-12	CI
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-11-16	CI
Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China	22-11-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Highlights

Filters